Kythera Biopharmaceuticals Inc (KYTH) 39.72 $KYTH
KYTHERA Acquires Worldwide Rights to Clinical Compound and Key Intellectual Property for Potential Novel Treatment of Hair Loss
GlobeNewswire - Tue Feb 10, 3:22PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that it has entered into separate license agreements with Actelion Pharmaceuticals Ltd. and the University of Pennsylvania for a novel approach for the treatment of hair loss, which together could enable KYTHERA to bring a new treatment to the very large and still highly unsatisfied hair loss market.
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 04, 6:00PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 2015 Leerink Global Healthcare Conference.
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals Submits Drug Application in Australia for Novel Submental Contouring Injectable Drug ATX-101
GlobeNewswire - Wed Feb 04, 3:22PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced its submission to Australia's Therapeutic Goods Administration (TGA) for ATX-101 (deoxycholic acid), its potential first-in-class treatment for improving submental fullness associated with submental (under the chin) fat. This milestone in KYTHERA's ATX-101 global development program follows regulatory applications in the U.S., Canada and Switzerland.
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Tue Feb 03, 7:25PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that on January 30, 2015, the Compensation Committee of the Company's Board of Directors granted five new employees options to purchase an aggregate of 52,500 shares of the Company's common stock. The exercise price of each option was $ 37.20, the closing trading price on the date of grant. The stock options were granted pursuant to the Company's 2014 Employment Commencement Incentive Plan, which was approved by the Company's Board of Directors in August 2014 under Rule 5653(c)(4) of The Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
KYTH: 39.72 (+0.62)
Ad Comm to review Kythera's double chin-busting drug
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 9:04AM CST
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals Announces Date of FDA Advisory Committee Review of ATX-101 for the Treatment of Submental Fullness
GlobeNewswire - Fri Jan 23, 8:00AM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced the Dermatology and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review KYTHERA's New Drug Application (NDA) for ATX-101 (deoxycholic acid) for improvement in the appearance of moderate to severe submental fullness in a half-day meeting on the morning of March 9, 2015.
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 05, 7:37PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco.
JPM: 59.67 (+0.10), KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals Appoints Hollings C. Renton to Board of Directors
GlobeNewswire - Mon Jan 05, 3:39PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that it has named Hollings C. Renton to its Board of Directors.
KYTH: 39.72 (+0.62), RIGL: 2.47 (+0.05)
Strength Seen in Kythera (KYTH): Stock Moves 5.5% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 8:25AM CST
Kythera (KYTH) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
BIIB: 391.66 (-0.45), KYTH: 39.72 (+0.62), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
KYTHERA Biopharmaceuticals to Present at the Goldman Sachs US Emerging / SMID Cap Growth Conference
GlobeNewswire - Fri Nov 14, 4:18PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Goldman Sachs US Emerging / SMID Cap Growth Conference in New York.
KYTH: 39.72 (+0.62)
Kythera net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:18AM CST
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals' (KYTH) CEO Keith Leonard on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:45PM CST
KYTH: 39.72 (+0.62)
Kythera misses 3Q profit forecasts
Automated Insights - Mon Nov 10, 6:24PM CST
CALABASAS, Calif. (AP) _ Kythera Biopharmaceuticals Inc. (KYTH) on Monday reported a loss of $22.5 million in its third quarter.
KYTH: 39.72 (+0.62)
KYTHERA misses by $0.11
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:22PM CST
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals Releases Third Quarter 2014 Operating Results
GlobeNewswire - Mon Nov 10, 3:11PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today reported financial results for its third quarter 2014 and provided an update on recent accomplishments.
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals to Release Third Quarter 2014 Operating Results
GlobeNewswire - Mon Nov 03, 5:30PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it will release its third quarter 2014 operating results and will host an investor call and webcast at 4:30 p.m. ET on Monday, November 10, 2014.
KYTH: 39.72 (+0.62)
KYTHERA Acquires Worldwide Rights to Clinical Compound and Key Intellectual Property for Potential Novel Treatment of Hair Loss
GlobeNewswire - Tue Feb 10, 3:22PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that it has entered into separate license agreements with Actelion Pharmaceuticals Ltd. and the University of Pennsylvania for a novel approach for the treatment of hair loss, which together could enable KYTHERA to bring a new treatment to the very large and still highly unsatisfied hair loss market.
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 04, 6:00PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 2015 Leerink Global Healthcare Conference.
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals Submits Drug Application in Australia for Novel Submental Contouring Injectable Drug ATX-101
GlobeNewswire - Wed Feb 04, 3:22PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced its submission to Australia's Therapeutic Goods Administration (TGA) for ATX-101 (deoxycholic acid), its potential first-in-class treatment for improving submental fullness associated with submental (under the chin) fat. This milestone in KYTHERA's ATX-101 global development program follows regulatory applications in the U.S., Canada and Switzerland.
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Tue Feb 03, 7:25PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that on January 30, 2015, the Compensation Committee of the Company's Board of Directors granted five new employees options to purchase an aggregate of 52,500 shares of the Company's common stock. The exercise price of each option was $ 37.20, the closing trading price on the date of grant. The stock options were granted pursuant to the Company's 2014 Employment Commencement Incentive Plan, which was approved by the Company's Board of Directors in August 2014 under Rule 5653(c)(4) of The Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
KYTH: 39.72 (+0.62)
Ad Comm to review Kythera's double chin-busting drug
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 9:04AM CST
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals Announces Date of FDA Advisory Committee Review of ATX-101 for the Treatment of Submental Fullness
GlobeNewswire - Fri Jan 23, 8:00AM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced the Dermatology and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review KYTHERA's New Drug Application (NDA) for ATX-101 (deoxycholic acid) for improvement in the appearance of moderate to severe submental fullness in a half-day meeting on the morning of March 9, 2015.
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 05, 7:37PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco.
JPM: 59.67 (+0.10), KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals Appoints Hollings C. Renton to Board of Directors
GlobeNewswire - Mon Jan 05, 3:39PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that it has named Hollings C. Renton to its Board of Directors.
KYTH: 39.72 (+0.62), RIGL: 2.47 (+0.05)
Strength Seen in Kythera (KYTH): Stock Moves 5.5% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 8:25AM CST
Kythera (KYTH) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
BIIB: 391.66 (-0.45), KYTH: 39.72 (+0.62), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
KYTHERA Biopharmaceuticals to Present at the Goldman Sachs US Emerging / SMID Cap Growth Conference
GlobeNewswire - Fri Nov 14, 4:18PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Goldman Sachs US Emerging / SMID Cap Growth Conference in New York.
KYTH: 39.72 (+0.62)
Kythera net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:18AM CST
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals' (KYTH) CEO Keith Leonard on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:45PM CST
KYTH: 39.72 (+0.62)
Kythera misses 3Q profit forecasts
Automated Insights - Mon Nov 10, 6:24PM CST
CALABASAS, Calif. (AP) _ Kythera Biopharmaceuticals Inc. (KYTH) on Monday reported a loss of $22.5 million in its third quarter.
KYTH: 39.72 (+0.62)
KYTHERA misses by $0.11
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:22PM CST
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals Releases Third Quarter 2014 Operating Results
GlobeNewswire - Mon Nov 10, 3:11PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today reported financial results for its third quarter 2014 and provided an update on recent accomplishments.
KYTH: 39.72 (+0.62)
KYTHERA Biopharmaceuticals to Release Third Quarter 2014 Operating Results
GlobeNewswire - Mon Nov 03, 5:30PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it will release its third quarter 2014 operating results and will host an investor call and webcast at 4:30 p.m. ET on Monday, November 10, 2014.
KYTH: 39.72 (+0.62)
